Search

Your search keyword '"Bourquin, Jean‐Pierre"' showing total 854 results

Search Constraints

Start Over You searched for: Author "Bourquin, Jean‐Pierre" Remove constraint Author: "Bourquin, Jean‐Pierre"
854 results on '"Bourquin, Jean‐Pierre"'

Search Results

201. Total Body Irradiation (TBI) in Pediatric Patients: A Single-center Experience after 30 Years of Low-dose Rate Irradiation

202. 14q32 rearrangements deregulating BCL11Bmark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia

203. Transcriptional Repression by RING Finger Protein TIF1β That Interacts with the KRAB Repressor Domain of KOX1

204. TNF receptor 2 is essential for RIP1-dependent cell death in refractory leukemia

205. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug resistant ALL

206. High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study

208. Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

210. Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

211. Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

212. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

213. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies

214. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group

215. Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma

216. Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia

217. USP7 cooperates with NOTCH1 to drive the oncogenic transcriptional program in T cell leukemia

218. P676: UPDATED RESULTS FROM THE TRIAL ITCC‐054/COG‐AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA.

220. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

221. Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing

222. Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia

223. SAF-B protein couples transcription and pre-mRNA splicing to SAR/MAR elements

224. A serine/arginine-rich nuclear matrix cyclophilin interacts with the C-terminal domain of RNA polymerase II

225. Humanised mouse models for haematopoiesis and infectious diseases

229. Abstract 4321: TNF receptor 2 is essential for RIP1-dependent cell death in refractory leukemia

230. From class waivers to precision medicine in paediatric oncology

233. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

234. Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing

237. Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia

238. A mass spectrometric-derived cell surface protein atlas

239. TNFR2 is required for RIP1-dependent cell death in human leukemia

240. SARS-CoV-2 Infection During Induction Chemotherapy in a Child With High-risk T-Cell Acute Lymphoblastic Leukemia (T-ALL)

241. The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

242. Flow diagnostics essential code: a simple and brief format for the summary of leukemia phenotyping

246. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL

247. Abstract IA10: Notch signaling and cancer

248. Drug Response Profiling to Identify Selective Pharmacological Activity in Drug Resistant ALL

Catalog

Books, media, physical & digital resources